Johnson & Johnson (NYSE:JNJ) said that additional data from several phase 3 studies found that the subcutaneous formulation of its IL-23 antagonist Tremfya (guselkumab) showed sustained remission in Crohn’s disease at two years.
In the trials, patients were either started with 400 mg subcutaneous Tremfya or 200 mg of the intravenous version. This was followed by subcutaneous maintenance doses of either 100 mg every eight weeks, or 200 mg every four weeks.
At week 96, clinical remission was 92% in the 100 mg group, and 93.4% in the 200 mg cohort. Figures for deep remission, which is achieving both clinical and endoscopic remission, were, respectively, 38.7% and 44.1%.
